Dosages

Likely Effective

• Attention Deficit and Hyperactivity Disorder (ADHD) —likely to improve symptoms and cognitive function D1
• Chronic kidney disease—likely to lower the risk of end-stage renal disease E1
• Dry eye—likely to ease symptoms M1, M2
• Early and preterm delivery—likely to prevent O1
• Hyperlipidemia —likely to lower triglycerides levels S1
• Insulin sensitivity—likely to increase sensitivity U1
• Liver failure — likely to lower triglycerides and raise HDL (“good”) cholesterol levels W1
• Migraine —likely to reduce migraine duration X1
• Non-alcoholic fatty liver disease —likely to decrease liver fat Y1, Y2
• Psoriasis —likely to ease symptoms BB1, BB2

May Be Effective

• Amyotrophic lateral sclerosis —may help prevent or delay onset B1
• Depression —may ease symptoms in older adults J1-J7
• Heart disease —may lower cholesterol, blood pressure, and heart rate Q1-Q3
• Heart failure —may provide benefit R1
• Infant support—may improve psychomotor and visual development T1, T2
• Pregnancy support —may reduce preterm birth and low birth weight, but may increase risk of large for gestational weight AA1-AA5
• Rheumatoid arthritis —may improve symptoms DD1, DD2

May Not Be Effective

• Age-related macular degeneration —may not provide benefit A1

Unlikely to Be Effective

• Asthma —unlikely to improve symptoms C1
• Crohn Disease —unlikely to help maintain remission G1
• Dementia —unlikely to provide benefit I1, I2
• Diabetes —unlikely to lower glucose, but may lower triglycerides K1

Not Enough Data to Assess

• Cognitive decline F1
• Cystic fibrosis H1
• Dysmenorrhea (Menstrual Pain) N1
• Drug-resistant epilepsy L1
• Heart attack C1
• Kidney failure V1
• Obesity Z1-Z3
• Psychosis CC1